Asset Details
Do you wish to reserve the book?
α-klotho as a biomarker of amyloid β levels in the cerebrospinal fluid
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
α-klotho as a biomarker of amyloid β levels in the cerebrospinal fluid
Do you wish to request the book?
α-klotho as a biomarker of amyloid β levels in the cerebrospinal fluid
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
α-klotho as a biomarker of amyloid β levels in the cerebrospinal fluid
2025
Overview
CSF
-klotho levels might affect Aβ40, Aβ42, and the Aβ42/40 ratio in the cerebrospinal fluid (CSF).
CSF
-klotho was assayed in ovariectomized rhesus macaques (NHPs) maintained on a Western-style diet (WSD) to assess the effect of estrogen hormone therapy (HT). CSF and serum
-klotho was also analyzed in females and males of different ages and whether it was associated with Aβ42, Aβ40, or the Aβ42/40 ratio. Furthermore, CSF and serum
-klotho were analyzed in women and men with dementia and controls and whether they were associated with CSF Aβ levels.
HT was associated with increased CSF
-klotho levels. Furthermore,
-klotho and Aβ levels were correlated in a species- and cognitive health-dependent fashion. Higher CSF and serum levels of
-klotho were seen in controls than in patients with dementia.
Understanding the species differences in the beneficial effects of
-klotho on CSF Aβ physiology should open new avenues for treating AD.
Publisher
Frontiers Media S.A
Subject
